/TCRX
TCRX Stock - TScan Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$0.90-3.79%
$0.04 (-3.79%) • Dec 19
62
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.6
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.79
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+234.9%upside
Target: $3.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TCRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.89 – $0.90
TARGET (TP)$3.00
STOP LOSS$0.82
RISK/REWARD1:27.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.03
52W High$3.43
52W Low$0.88
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.82M | $21.05M | $13.54M | $10.14M | $1.08M |
| Gross Profit | $2.82M | $21.05M | $13.54M | $10.14M | $-19,492,000 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | -1796.5% |
| Operating Income | $-134,821,000 | $-93,458,000 | $-66,636,000 | $-48,641,000 | $-26,233,000 |
| Net Income | $-127,499,000 | $-89,218,000 | $-66,221,000 | $-48,625,000 | $-26,127,000 |
| Net Margin | -4527.7% | -423.9% | -489.3% | -479.5% | -2408.0% |
| EPS | $-1.14 | $-1.36 | $-2.74 | $-2.03 | $-1.04 |
Company Overview
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
75%
Hold / Neutral
1
25%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish1 Neutral/Bearish
Price Targets
$10
Average Target
↑ 1053.7% Upside
Now
$8
Low
$10
Average
$12
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 14th 2025 | Morgan Stanley | Downgrade | Equal Weight | - |
| May 16th 2024 | BTIG Research | Initiation | Buy | $12 |
| May 13th 2024 | Needham | Initiation | Buy | $11 |
| June 22nd 2023 | Wedbush | Initiation | Outperform | $8 |
Earnings History & Surprises
TCRXBeat Rate
61%
Last 18 quarters
Avg Surprise
-1.5%
EPS vs Estimate
Beats / Misses
11/6
1 met exactly
Latest EPS
$-0.28
Q4 2025
EPS Surprise History
Q1 24
+30.0%
$-0.21vs$-0.30
Q2 24
-28.0%
$-0.32vs$-0.25
Q3 24
+6.7%
$-0.28vs$-0.30
Q4 24
+10.7%
$-0.25vs$-0.28
Q1 25
-7.4%
$-0.29vs$-0.27
Q2 25
+7.1%
$-0.26vs$-0.28
Q3 25
0.0%
$-0.28vs$-0.28
Q4 25
+20.0%
$-0.28vs$-0.35
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 4, 2026 | $-0.27 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.35 | $-0.28 | +20.0% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.28 | $-0.28 | 0.0% | = MET |
Q2 2025 | May 6, 2025 | $-0.28 | $-0.26 | +7.1% | ✓ BEAT |
Q1 2025 | Mar 5, 2025 | $-0.27 | $-0.29 | -7.4% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.28 | $-0.25 | +10.7% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-0.30 | $-0.28 | +6.7% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-0.25 | $-0.32 | -28.0% | ✗ MISS |
Q1 2024 | Mar 6, 2024 | $-0.30 | $-0.21 | +30.0% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.43 | $-0.24 | +44.2% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.76 | $-0.51 | +32.9% | ✓ BEAT |
Q2 2023 | May 10, 2023 | $-0.73 | $-0.93 | -27.4% | ✗ MISS |
Q1 2023 | Mar 8, 2023 | $-0.73 | $-0.78 | -6.8% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-0.73 | $-0.67 | +8.2% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $-0.76 | $-0.63 | +17.1% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $-0.69 | $-0.67 | +2.9% | ✓ BEAT |
Q1 2022 | Mar 9, 2022 | $-0.73 | $-0.38 | +47.9% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.68 | $-0.80 | -17.6% | ✗ MISS |
Q3 2021 | Aug 19, 2021 | $-2.87 | $-7.69 | -167.9% | ✗ MISS |
Q3 2021 | Jul 15, 2021 | — | $-0.32 | — | — |
Latest News
TScan Therapeutics Announced Saturday, Updated Data from the ALLOHA Phase 1 Heme Trial; 3/3 Of TSC-101-treated Patients Who Reached Two-year Follow-up Remained Relapse-free Vs. 1/4 In Control Arm
📈 PositiveBenzinga•Dec 7, 2025, 10:49 PM
HC Wainwright & Co. Maintains Buy on TScan Therapeutics, Lowers Price Target to $7
➖ NeutralBenzinga•Nov 13, 2025, 12:53 PM
TScan Therapeutics Q3 EPS $(0.28) Beats $(0.30) Estimate, Sales $2.511M Beat $1.980M Estimate
📈 PositiveBenzinga•Nov 12, 2025, 12:13 PM
BTIG Downgrades TScan Therapeutics to Neutral
➖ NeutralBenzinga•Nov 4, 2025, 11:23 AM
Needham Maintains Buy on TScan Therapeutics, Lowers Price Target to $6
➖ NeutralBenzinga•Nov 4, 2025, 10:30 AM
TScan Therapeutics shares are trading lower. The company announced regulatory and clinical program updates, implementation of a workforce reduction of approximately 30%, and extension of its cash runway into the second half of 2027.
📉 NegativeBenzinga•Nov 3, 2025, 02:22 PM
TScan Therapeutics Reaches Agreement With FDA On TSC-101 Study Design; Announces 30% Workforce Reduction To Focus On Heme Program And Prioritization Of Advancing TSC-101
➖ NeutralBenzinga•Nov 3, 2025, 11:34 AM
TScan Therapeutics To Present New Research On T Cell Therapies At ACR Convergence 2025 In Chicago
📈 PositiveBenzinga•Sep 17, 2025, 11:03 AM
Frequently Asked Questions about TCRX
What is TCRX's current stock price?
TScan Therapeutics, Inc. (TCRX) is currently trading at $0.90 per share. The stock has moved -3.79% today.
What is the analyst price target for TCRX?
The average analyst price target for TCRX is $3.00, based on 1 analyst.
What sector is TScan Therapeutics, Inc. in?
TScan Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is TCRX's market cap?
TScan Therapeutics, Inc. has a market capitalization of $0.05 billion, making it a small-cap company.
Does TCRX pay dividends?
No, TScan Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACET
Adicet Bio, Inc.
$0.49
Mkt Cap: $0.0B
ACRV
Acrivon Therapeutics, Inc. Common Stock
$2.16
Mkt Cap: $0.1B
FBIO
Fortress Biotech, Inc.
$3.54
Mkt Cap: $0.1B
IMUX
Immunic, Inc.
$0.57
Mkt Cap: $0.1B
LITS
Lite Strategy, Inc.
$1.43
Mkt Cap: $0.1B
NTRB
Nutriband Inc.
$4.49
Mkt Cap: $0.1B
PMVP
PMV Pharmaceuticals, Inc.
$1.24
Mkt Cap: $0.1B
RLMD
Relmada Therapeutics, Inc.
$4.35
Mkt Cap: $0.3B
VXRT
Vaxart, Inc.
$0.35
Mkt Cap: $0.1B
XBIT
XBiotech Inc.
$2.50
Mkt Cap: $0.1B
Explore stocks similar to TCRX for comparison